Vycor Medical Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2017
March 30, 2018 at 09:00 am EDT
Share
Vycor Medical Inc. reported consolidated earnings results for the year ended December 31, 2017. For the year, the company reported revenue of $1,384,971 compared to $1,452,714 a year ago. Operating loss was $1,312,563 compared to $1,591,378 a year ago. Loss before credit for income taxes was $1,477,045 compared to $1,652,280 a year ago. Net Loss was $1,477,045 as compared to $1,652,280 a year ago. Net loss available to common shareholders was $1,801,415 or $0.10 per basic and diluted share compared to $1,832,007 or $0.17 per basic and diluted share a year ago. Non GAAP operating loss before depreciation and amortization was $462,616 as compared to $594,273 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
